Consistent with these findings, prior work reported that alkyl-terminated AuNPs (Au3@PEG-octadecyl30% NPs, sub-15 nm) can down-regulate genes that are enriched in the downstream of the IL-17 signaling pathway, leading to reduced inflammation and prevention of psoriasis progression with efficacy comparable to standard steroid or vitamin D-based therapies [43]. This evidence concerns the gene IL17A and psoriasis.